Medical Services (CE) (USOTC:MSITF)
Historical Stock Chart
From Aug 2019 to Aug 2024
![Click Here for more Medical Services (CE) Charts. Click Here for more Medical Services (CE) Charts.](/p.php?pid=staticchart&s=NO%5EMSITF&p=8&t=15)
EDMONTON, Alberta, Aug. 26 /PRNewswire-FirstCall/ -- Medical Services International Inc. (Pink Sheets: MSITF) wishes to announce that it has signed an agreement with a US biotech firm based in New Jersey that specializes in developing new products.
As part of the agreement this firm will be responsible for the completion of all necessary US testing required that hasn't been completed and filing of documents necessary to get the VScan TB and VScan Hepatitis C approved for use in the United States as medical device. This firm will be responsible for obtaining regulatory approval, marketing and distribution of the two VScan test kits. Their marketing program indicates that they will sell in excess of 3.5 million kits over a two year period once regulatory approval is obtained. They have also received the option to obtain regulatory approval and market other VScan products in the United States. Such options are based on very strict performance criteria.
About VScan
The VScan rapid test kit is a single use, easy to use, test for the screening of HIV1&2, Hepatitis B&C, Tuberculosis (TB),Dengue Fever, Malaria, West Nile, Syphilis and Prostate Cancer. The kits cannot be sold in Canada.
Medical Services International Inc. trades in the United states on the NQB Pink Sheets under the symbol "MSITF". For further information, please contact Robert Talbot at (780) 430 6363 or http://www.medicalservicesintl.com/ or http://www.minerva-biotech.com/.
NOTE: Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that may cause results to differ materially.
Such risks, uncertainties and other factors include but are not limited to new economic conditions, risk in product development, market acceptance of new products and continuing market demand, level of competition and other factors described in Company reports and other filings with regulatory bodies.
DATASOURCE: Medical Services International Inc.
CONTACT: Robert Talbot of Medical Services International Inc.,
+1-780-430-6363
Web site: http://www.medicalservicesintl.com/